Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

NCT03552718 is registered in ClinicalTrials.gov with NantBioScience, Inc. as lead sponsor.

NCT NCT03552718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03552718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
Lead sponsor
NantBioScience, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 10, 2018
Completion date
March 18, 2025
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, head and neck squamous cell carcinoma, liver cancer, melanoma, non small cell lung cancer, pancreatic cancer